glp 1 receptors Frontiers GLP-1 Receptor Agonist Services for

doi: 10.3892/etm.2016.3742 [DOI] [PMC free article] [PubMed] [Google Scholar] 86

doi: 10.2337/dc20-1997

Background: How GLP-1s evolved from diabetes treatment to anti-obesity medications Glucagon-like peptide-1 receptor agonists (GLP-1s) have a notable history in medical treatment, beginning as therapies for type 2 diabetes and later emerging as highly effective agents for weight loss

An extensive menu of obesity drugs that work via distinct biological mechanisms means that patients will have more options to try

Ethics declarations Competing interests E.M

Accordingly, moderate lean tissue decline observed during GLP-1RA-induced weight loss could be interpreted as a physiological component of body composition change rather than evidence of pathological sarcopenia, unless accompanied by functional deterioration